Omeros Corp Chairman, CEO, and President Gregory A. Demopulos MD filed a Form 4 on October 30, 2026, disclosing the grant of 500,000 performance stock options in Omeros Corp common stock on October 28, 2026, with an exercise price of $17.88 per share and an expiration date of October 28, 2031.

Key Highlights

  • Grant date: October 28, 2026, covering 500,000 performance stock options (right to buy) in Omeros Corp common stock.
  • Exercise price: $17.88 per share, equal to the grant-date closing price, acquired at a price of $0.
  • Vesting structure: Four equal tranches, each requiring both a stock-price hurdle and a continued-service condition to be met.
  • Stock-price hurdles: $25.00, $30.00, $35.00, and $40.00 per share, measured by the 30-consecutive-trading-day aggregate volume-weighted average price.
  • Service condition: 25% of each tranche becomes eligible on the first anniversary of the grant date; the remainder vests in equal monthly installments over the following 36 months.
  • No shares vested: According to the filing, "No portion of the option was vested, and no shares were issued, on the grant date."
  • Post-transaction derivative holdings: 500,000 performance stock options beneficially owned directly following the reported transaction.

Performance-Based Option Award Details for Gregory A. Demopulos at Omeros Corp

Gregory A. Demopulos MD, Chairman, CEO, and President of Omeros Corp (NASDAQ:OMER), reported the acquisition of a performance stock option covering 500,000 shares of common stock, transacted on October 28, 2026, with an expiration date of October 28, 2031. The filing reports the option was acquired at a price of $0, with an exercise price of $17.88 per share, matching the grant-date closing price.

According to the filing, the option is divided into four equal tranches. Each tranche is subject to two separate conditions: a stock-price hurdle and a continued-service requirement. The price hurdles are $25.00, $30.00, $35.00, and $40.00 per share, respectively, evaluated using the aggregate volume-weighted average price of the registrant's common stock over 30 consecutive trading days, at any point during the five-year option term. The filing states these hurdles "represent appreciation of approximately 40%, 68%, 96% and 124%, respectively, above the grant-date closing price of $17.88 per share."

For the continued-service condition, the filing explains that 25% of the shares in each tranche become eligible for vesting on the first anniversary of the grant date, with the remaining shares becoming eligible in equal monthly installments over the following 36 months. The filing was signed by Peter B. Cancelmo as Attorney-in-Fact on October 30, 2026. Following the transaction, Demopulos directly holds 500,000 derivative securities as reported.

What Was Disclosed

Omeros Corp's Chairman, CEO, and President reported receiving a performance stock option for 500,000 shares of common stock on October 28, 2026, at an exercise price of $17.88, with vesting contingent on both stock-price milestones and continued service over a five-year term.